Cargando…

BET Proteins as Attractive Targets for Cancer Therapeutics

Transcriptional dysregulation is a hallmark of cancer and can be an essential driver of cancer initiation and progression. Loss of transcriptional control can cause cancer cells to become dependent on certain regulators of gene expression. Bromodomain and extraterminal domain (BET) proteins are epig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarnik, Joanna, Popławski, Tomasz, Tokarz, Paulina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538173/ https://www.ncbi.nlm.nih.gov/pubmed/34681760 http://dx.doi.org/10.3390/ijms222011102

Ejemplares similares

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

Integrins as attractive targets for cancer therapeutics
por: Li, Meng, et al.
Publicado: (2021)

Biomolecular computers with multiple restriction enzymes
por: Sakowski, Sebastian, et al.
Publicado: (2017)

Increased Sensitivity of PBMCs Isolated from Patients with Rheumatoid Arthritis to DNA Damaging Agents Is Connected with Inefficient DNA Repair
por: Galita, Grzegorz, et al.
Publicado: (2020)

SNP in PTPN22, PADI4, and STAT4 but Not TRAF1 and CD40 Increase the Risk of Rheumatoid Arthritis in Polish Population
por: Budlewski, Tomasz, et al.
Publicado: (2023)

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer
por: Asangani, Irfan A., et al.
Publicado: (2014)

Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016)

Polymorphisms in DNA Repair Genes and Association with Rheumatoid Arthritis in a Pilot Study on a Central European Population
por: Galita, Grzegorz, et al.
Publicado: (2023)

SENP Proteases as Potential Targets for Cancer Therapy
por: Tokarz, Paulina, et al.
Publicado: (2021)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Protein Kinase C: An Attractive Target for Cancer Therapy
por: Marengo, Barbara, et al.
Publicado: (2011)

Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma
por: Tanaka, Yasuo, et al.
Publicado: (2018)

Viral Hijacking of BET Proteins
por: Chen, Irene P., et al.
Publicado: (2022)

Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers
por: Vízkeleti, Laura, et al.
Publicado: (2023)

BCL-2 protein family: attractive targets for cancer therapy
por: Kaloni, Deeksha, et al.
Publicado: (2022)

Nrf2 Is an Attractive Therapeutic Target for Retinal Diseases
por: Nakagami, Yasuhiro
Publicado: (2016)

Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
por: Fu, Lei-lei, et al.
Publicado: (2015)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer
por: Wyce, Anastasia, et al.
Publicado: (2013)

Targeting BET Proteins Decreases Hyaluronidase-1 in Pancreatic Cancer
por: Kumar, Krishan, et al.
Publicado: (2023)

BET Signaling: A Novel Therapeutic Target for Pulmonary Hypertension?
por: Chen, Lingdan, et al.
Publicado: (2020)

Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy
por: Wang, Zhi-Qiang, et al.
Publicado: (2023)

Inflammatory Cytokine: An Attractive Target for Cancer Treatment
por: Lee, Hyang-Mi, et al.
Publicado: (2022)

BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
por: To, Kenneth K. W., et al.
Publicado: (2023)

BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
por: Henssen, Anton, et al.
Publicado: (2013)

Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents
por: Spratt, Austin N., et al.
Publicado: (2021)

Cancer testis antigen subfamilies: Attractive targets for therapeutic vaccine (Review)
por: Ren, Shengnan, et al.
Publicado: (2023)

The World of Pseudogenes: New Diagnostic and Therapeutic Targets in Cancers or Still Mystery Molecules?
por: Stasiak, Maciej, et al.
Publicado: (2021)

BET Protein-Mediated Transcriptional Regulation in Heart Failure
por: Ijaz, Talha, et al.
Publicado: (2021)

Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
por: Manzotti, Gloria, et al.
Publicado: (2019)

Pharmacologic Targeting of BET Proteins Attenuates Hyperuricemic Nephropathy in Rats
por: Xiong, Chongxiang, et al.
Publicado: (2021)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Nucleolar Proteins and Non-Coding RNAs: Roles in Renal Cancer
por: Popławski, Piotr, et al.
Publicado: (2021)

Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization
por: Zhang, Pingzhao, et al.
Publicado: (2017)

Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors
por: Janouskova, Hana, et al.
Publicado: (2017)

Interleukin-17 regulation: an attractive therapeutic approach for asthma
por: Park, Seoung Ju, et al.
Publicado: (2010)

The nucleocapsid protein of zoonotic betacoronaviruses is an attractive target for antiviral drug discovery
por: Lang, Yuekun, et al.
Publicado: (2021)

Targeting TMEM88 as an Attractive Therapeutic Strategy in Malignant Tumors
por: Cai, Ming, et al.
Publicado: (2022)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tqbktvshj72etnpn5vrg2a8ctj